KR20240156407A - Iap 길항제 화합물과 조합 요법을 이용한 암 치료 방법 - Google Patents

Iap 길항제 화합물과 조합 요법을 이용한 암 치료 방법 Download PDF

Info

Publication number
KR20240156407A
KR20240156407A KR1020247033050A KR20247033050A KR20240156407A KR 20240156407 A KR20240156407 A KR 20240156407A KR 1020247033050 A KR1020247033050 A KR 1020247033050A KR 20247033050 A KR20247033050 A KR 20247033050A KR 20240156407 A KR20240156407 A KR 20240156407A
Authority
KR
South Korea
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
dexamethasone
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247033050A
Other languages
English (en)
Korean (ko)
Inventor
마틴 존 심스
조지 앨버트 워드
도모코 스미스
고탐 보르타쿠르
Original Assignee
오츠카 세이야쿠 가부시키가이샤
더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 오츠카 세이야쿠 가부시키가이샤, 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 filed Critical 오츠카 세이야쿠 가부시키가이샤
Publication of KR20240156407A publication Critical patent/KR20240156407A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020247033050A 2022-03-04 2023-03-03 Iap 길항제 화합물과 조합 요법을 이용한 암 치료 방법 Pending KR20240156407A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263316680P 2022-03-04 2022-03-04
US63/316,680 2022-03-04
PCT/US2023/063669 WO2023168394A1 (en) 2022-03-04 2023-03-03 Methods of treating cancer with iap antagonist compounds and combination therapies

Publications (1)

Publication Number Publication Date
KR20240156407A true KR20240156407A (ko) 2024-10-29

Family

ID=85792184

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247033050A Pending KR20240156407A (ko) 2022-03-04 2023-03-03 Iap 길항제 화합물과 조합 요법을 이용한 암 치료 방법

Country Status (7)

Country Link
US (1) US20250186451A1 (https=)
EP (1) EP4486352A1 (https=)
JP (1) JP2025508016A (https=)
KR (1) KR20240156407A (https=)
AU (1) AU2023229084A1 (https=)
TW (1) TW202345849A (https=)
WO (1) WO2023168394A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR122022015241B1 (pt) 2013-12-20 2023-09-26 Astex Therapeutics Limited Compostos heterocíclicos bicíclicos intermediários para a preparação de um composto de fórmula (i)
CN120379671A (zh) * 2022-10-18 2025-07-25 辉瑞公司 用于治疗癌症的化合物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8546399B2 (en) 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
BR122022015241B1 (pt) 2013-12-20 2023-09-26 Astex Therapeutics Limited Compostos heterocíclicos bicíclicos intermediários para a preparação de um composto de fórmula (i)
GB201919219D0 (en) * 2019-12-23 2020-02-05 Otsuka Pharma Co Ltd Cancer biomarkers

Also Published As

Publication number Publication date
US20250186451A1 (en) 2025-06-12
AU2023229084A1 (en) 2024-10-17
TW202345849A (zh) 2023-12-01
JP2025508016A (ja) 2025-03-21
EP4486352A1 (en) 2025-01-08
WO2023168394A1 (en) 2023-09-07

Similar Documents

Publication Publication Date Title
US20240091234A1 (en) Treatment of b-cell malignancies by a combination jak and pi3k inhibitors
JP7638981B2 (ja) 置換４－アミノイソインドリン－１，３－ジオン化合物および組合せ使用のための第２の活性剤
KR102449712B1 (ko) 아미노티아졸 화합물 및 이의 용도
AU2014360758B2 (en) Methods of treating and preventing alloantibody driven chronic graft versus host disease
CN114008024A (zh) 具有铁死亡诱导活性的化合物以及使用其的方法
KR20240156407A (ko) Iap 길항제 화합물과 조합 요법을 이용한 암 치료 방법
WO2021100677A1 (ja) 併用医薬
KR20240144146A (ko) Malt1 저해약을 유효 성분으로서 포함하는 암 치료제
KR20210115375A (ko) Pi3 키나아제 저해제 및 btk 저해제를 포함하는 조성물
US20220227716A1 (en) Benzimidazole and hydrogenated carbazole derivatives as gpx4 inhibitors
HK40122816A (en) Treatment of b-cell malignancies by a combination jak and pi3k inhibitor
HK40049323A (en) Treatment of b-cell malignancies by a combination jak and pi3k inhibitor
CA3119395A1 (en) Combination of a mcl-1 inhibitor and midostaurin, uses and pharmaceutical compositions thereof
BR122021024771B1 (pt) Uso de uma combinação de inibidores de jak1/2e pi3ksigma no tratamento de mielofibrose
HK1233180A1 (en) Treatment of b-cell malignancies by a combination jak and pi3k inhibitor
HK1233180B (en) Treatment of b-cell malignancies by a combination jak and pi3k inhibitor
BR112016023322B1 (pt) Uso de uma combinação de inibidores de jak e pi3ksigma

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R11-asn-PN2301

R11 Change to the name of applicant or owner or transfer of ownership requested

Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R11-ASN-PN2301 (AS PROVIDED BY THE NATIONAL OFFICE)